Key facts
- This page summarizes Michelle Renee Griffin's Form 4 filing for Acer Therapeutics Inc..
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 16 Mar 2023, 16:37.
Michelle Renee Griffin - 14 Mar 2023 Form 4 Insider Report for Acer Therapeutics Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 14 Mar 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 16 Mar 2023, 16:37:10 UTC
- Prior SEC filing
- 08 Mar 2023
- Next SEC filing
- 29 Mar 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Harry S. Palmin, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Michelle Renee Griffin filed Form 4 for Acer Therapeutics Inc. on 16 Mar 2023.
Change
- Previous filing in this sequence was filed on 08 Mar 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ACER
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +20,000
- Change %
- Price
- $0.000000
- Shares after
- 20,000
- Date
- 14 Mar 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 20,000
- Exercise price
- $1.67
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The option, which is made as part of the Issuer's 2023 annual compensation cycle, vests and becomes exercisable in full on March 14, 2024.